Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.34 |
| ▸ | TDP2 | O95551 | 1/20 | 0.34 |
| ▸ | NSD2 | O96028 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29864428 | 1.00 | PBRM1 (0.34) | PBRM1TDP2NSD2HTR1AHTR2A | |
| SCHEMBL30002194 | 0.88 | MAOA (0.38) | TDP2NSD2HTR1AHTR2AHSD17B10 | |
| SCHEMBL6635128 | 0.88 | MAOA (0.38) | TDP2NSD2HTR1AHTR2AHSD17B10 | |
| SCHEMBL12446468 | 0.84 | HTR2A (0.33) | TDP2NSD2HTR1AHTR2A | |
| SCHEMBL10187270 | 0.79 | CASP1 (0.38) | PBRM1DRD2CASP1CASP7HSD17B10 | |
| SCHEMBL23376841 | 0.75 | PBRM1 (0.38) | PBRM1CASP1CASP7HSD17B10 | |
| SCHEMBL24858516 | 0.75 | PBRM1 (0.34) | PBRM1HTR1AHTR2ADRD2CASP1 | |
| SCHEMBL22852089 | 0.75 | PBRM1 (0.34) | PBRM1CASP1CASP7HSD17B10 | |
| SCHEMBL24490882 | 0.75 | PBRM1 (0.34) | PBRM1CASP1CASP7HSD17B10 | |
| SCHEMBL527206 | 0.75 | S100A4 (0.42) | PBRM1NSD2HTR1AHTR2ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028363-A1 | CHIRAL SYNTHESIS OF A TERTIARY ALCOHOL | RECURIUM IP HOLDINGS LLC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20250361241-A1 | HPK1 INHIBITOR AND MEDICAL USE THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2025-11-27 | — | — | US | disclosed |
| EP-4619406-A1 | TRICYCLIC COMPOUNDS | Schrödinger, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-12410204-B2 | Chiral synthesis of a tertiary alcohol | RECURIUM IP HOLDINGS, LLC (US) | 2025-09-09 | — | — | US | disclosed |
| EP-4538274-A1 | HPK1 INHIBITOR AND MEDICAL USE THEREOF | Betta Pharmaceuticals Co., Ltd (CN) | 2025-04-16 | — | — | EP | disclosed |
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2024-07-11 | — | — | US | disclosed |
| WO-2024107393-A1 | TRICYCLIC COMPOUNDS | SCHRÖDINGER, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2023237085-A1 | HPK1 INHIBITOR AND MEDICAL USE THEREOF | 贝达药业股份有限公司 | 2023-12-14 | — | — | WO | disclosed |
| WO-2012038521-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-03-29 | — | — | WO | disclosed |
| EP-2432555-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | Incyte Corporation (US) | 2012-03-28 | — | — | EP | disclosed |
| WO-2012013754-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-02-02 | — | — | WO | disclosed |
| WO-2012013754-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-02-02 | — | — | WO | disclosed |
| WO-2012001107-A1 | PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012001040-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-01-05 | — | — | WO | disclosed |
| US-20110130384-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-02 | — | — | US | disclosed |
| EP-2298731-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-03-23 | — | — | EP | disclosed |
| WO-2010135650-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2010-11-25 | — | — | WO | disclosed |
| US-20100298334-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298334-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | PBRM1 263/4885TDP2 1495/4885NSD2 412/4885 |
| US-12410204-B2 | Chiral synthesis of a tertiary alcohol | ADH1A, ADH1C, ADH5 | PBRM1 354/4885TDP2 3952/4885NSD2 4763/4885 |
| US-20250361241-A1 | HPK1 INHIBITOR AND MEDICAL USE THEREOF | STK11, STK35, STK10 | PBRM1 897/4885TDP2 1776/4885NSD2 3004/4885 |
| US-20110130384-A1 | AMIDE COMPOUND | GPR52, CNR2, ARRB1 | PBRM1 2809/4885TDP2 3911/4885NSD2 1711/4885 |
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | WEE1, WEE2, DCLRE1B | PBRM1 1935/4885TDP2 386/4885NSD2 1908/4885 |
| US-20260028363-A1 | CHIRAL SYNTHESIS OF A TERTIARY ALCOHOL | ADH1A, ADH1C, ADH5 | PBRM1 236/4885TDP2 3449/4885NSD2 3612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.